Axcan Pharma Closes Fiscal 2006 With Record Annual Revenue Of $292.3 Million, A 16.3% Increase Over Last Year

Fiscal 2006 Revenue of $292.3 Million, Representing Growth of 16.3% Compared to Fiscal 2005 -- Diluted Income Per Share for the Fourth Quarter of Fiscal 2006 Amounted to $0.17 After One-Time Charges of $0.05, Versus Diluted Income per Share of $0.19 a Year Earlier